Docosahexaenoic acid therapy in peroxisomal diseases: Results of a double-blind, randomized trial

Neurology

Volumn 75, Issue 9, 2010, Pages 826-830

  Paker, A M ^a   Sunness, J S ^d   Brereton, N H ^c   Speedie, L J ^b   Albanna, L ^b   Dharmaraj, S ^e   Moser, A B ^b   Jones, R O ^b   Raymond, G V ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d GREATER BALTIMORE MEDICAL CENTER   (United States)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; PLACEBO;

ADRENOLEUKODYSTROPHY; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ELECTRORETINOGRAM; FATTY ACID OXIDATION; FOLLOW UP; GROWTH; HUMAN; INFANTILE REFSUM DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; VISION; ZELLWEGER SYNDROME; BODY HEIGHT; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DRUG EFFECTS; ELECTRORETINOGRAPHY; INFANT; NEWBORN; PATHOPHYSIOLOGY; PEROXISOMAL DISORDERS; PHYSIOLOGY; PRESCHOOL CHILD; REFSUM DISEASE, INFANTILE;

BODY HEIGHT; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; ELECTRORETINOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; PEROXISOMAL DISORDERS; REFSUM DISEASE, INFANTILE; TREATMENT OUTCOME; VISUAL PERCEPTION; ZELLWEGER SYNDROME;

EID: 77956366856     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f07061     Document Type: Article

References (13)

1. Goldfischer S, Moore CL, Johnson AB, et al. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 1973;182:62-64.
2. Gould S, Raymond G, Valle D. The peroxisome biogenesis disorders. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill; 2001:3181-3217.
3. Wilson GN, Holmes RG, Custer J, et al. Zellweger syndrome: diagnostic assays, syndrome delineation, and potential therapy. Am J Med Genet 1986;24:69-82.
4. Wanders RJ, Tager JM. Lipid metabolism in peroxisomes in relation to human disease. Mol Aspects Med 1998;19: 69-154.
5. Neuringer M, Connor WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA 1986;83:4021-4025.
6. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992;583:171-182.
7. Martinez M, Pineda M, Vidal R, Conill J, Martin B. Do-cosahexaenoic acid: a new therapeutic approach to peroxisomal-disorder patients\experience with two cases. Neurology 1993;43:1389-1397.
8. Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001;16:309-316.
9. Raymond GV, Moser A, Moser H. Docosahexaenoic acid therapy in peroxisome biogenesis disorders. Ann Neurol 1997;42(suppl):P41. Abstract.
10. Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999;45:100-110.
11. Moser AE, Singh I, Brown FR III, et al. The cerebrohepa-torenal (Zellweger) syndrome: increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis. N Engl J Med 1984;310:1141-1146.
12. Moser AB, Jones DS, Raymond GV, Moser HW. Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem Res 1999;24:187-197.
13. Martinez M, Vazquez E. MRI evidence that docosahexae-noic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 1998;51:26-32.